170 related articles for article (PubMed ID: 38658567)
1. ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.
Böpple K; Oren Y; Henry WS; Dong M; Weller S; Thiel J; Kleih M; Gaißler A; Zipperer D; Kopp HG; Aylon Y; Oren M; Essmann F; Liang C; Aulitzky WE
Cell Death Dis; 2024 Apr; 15(4):290. PubMed ID: 38658567
[TBL] [Abstract][Full Text] [Related]
2. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
3. Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.
Wang Y; Zhao G; Condello S; Huang H; Cardenas H; Tanner EJ; Wei J; Ji Y; Li J; Tan Y; Davuluri RV; Peter ME; Cheng JX; Matei D
Cancer Res; 2021 Jan; 81(2):384-399. PubMed ID: 33172933
[TBL] [Abstract][Full Text] [Related]
4. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
[TBL] [Abstract][Full Text] [Related]
5. Epithelial/mesenchymal heterogeneity of high-grade serous ovarian carcinoma samples correlates with miRNA let-7 levels and predicts tumor growth and metastasis.
Chirshev E; Hojo N; Bertucci A; Sanderman L; Nguyen A; Wang H; Suzuki T; Brito E; Martinez SR; Castañón C; Mirshahidi S; Vazquez ME; Wat P; Oberg KC; Ioffe YJ; Unternaehrer JJ
Mol Oncol; 2020 Nov; 14(11):2796-2813. PubMed ID: 32652647
[TBL] [Abstract][Full Text] [Related]
6. PTPN13 Participates in the Regulation of Epithelial-Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells.
Aptecar L; Puech C; Lopez-Crapez E; Peter M; Coopman P; D'Hondt V; Freiss G
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895093
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
Noriega-Rivera R; Rivera-Serrano M; Rabelo-Fernandez RJ; Pérez-Santiago J; Valiyeva F; Vivas-Mejía PE
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887085
[TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
11. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
13. SUSD2 promotes cancer metastasis and confers cisplatin resistance in high grade serous ovarian cancer.
Xu Y; Miao C; Jin C; Qiu C; Li Y; Sun X; Gao M; Lu N; Kong B
Exp Cell Res; 2018 Feb; 363(2):160-170. PubMed ID: 29305171
[TBL] [Abstract][Full Text] [Related]
14. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
[TBL] [Abstract][Full Text] [Related]
16. The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells.
Fortunato A
Cell Oncol (Dordr); 2017 Aug; 40(4):367-378. PubMed ID: 28593575
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease.
Haley J; Tomar S; Pulliam N; Xiong S; Perkins SM; Karpf AR; Mitra S; Nephew KP; Mitra AK
Oncotarget; 2016 May; 7(22):32810-20. PubMed ID: 27147568
[TBL] [Abstract][Full Text] [Related]
18. Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis.
Wu YC; Huang CS; Hsieh MS; Huang CM; Setiawan SA; Yeh CT; Kuo KT; Liu SC
Aging (Albany NY); 2024 Jan; 16(1):627-647. PubMed ID: 38206305
[TBL] [Abstract][Full Text] [Related]
19. The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival.
Rae S; Spillane C; Blackshields G; Madden SF; Keenan J; Stordal B
Hum Cell; 2022 Sep; 35(5):1547-1559. PubMed ID: 35794446
[TBL] [Abstract][Full Text] [Related]
20. DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Yamaguchi N; Mimoto R; Yanaihara N; Imawari Y; Hirooka S; Okamoto A; Yoshida K
Tumour Biol; 2015 Aug; 36(8):5913-23. PubMed ID: 25712377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]